Predictive Factors for Endoscopic Stenting Patency and Patient Survival in Unresectable Malignant Biliary Obstruction: A Cohort Study at a Tertiary Institution

Aim: Factors associated with the biliary stent dysfunction and long-term survival are not clearly established. To analyze factors associated with stent patency in palliative biliary drainage (BD) and to evaluate the factors associated with patient survival. Material and M ethods: Observational retrospective study with consecutive inclusion of patients with unresectable biliopancreatic tumours who underwent BD by ERCP between January-2015 and December-2016. To analyze the factors associated with patient survival, the hazard ratio obtained through a Cox model was used. The follow-up review period was limited up to January 2018 (from at least one year after the endoscopic procedure) or the patient´s death. Results: Forty-four patients were included during the study period. The clinical success rate of overall biliary stents was 93.2% and total AE rate was 18.2%. The basal biliary stent was functional in 79.5%; in the remaining cases, endoscopic reinterventions were necessary. The median time until the loss of stent patency was 131 days (Q1-Q3; 85-387days). None of the parameters analyzed were associated with stent dysfunction. The patients who required endoscopic reinterventions had a longer survival time (median of 422days [Q1-Q3; 281-520] vs 162days [Q1-Q3; 37-264], p=0.001). Oncological treatment, partially covered self-expandable metal stent, and high albumin were statistically associated with a longer survival. Conclusions: The majority of biliary stents were functional, without the need to repeat the ERCP sessions. The need for stent repermeabilization did not negatively influence patient survival.

[1]  A. Irisawa,et al.  A Prospective Multicenter Study of a Fully Covered Metal Stent in Patients with Distal Malignant Biliary Obstruction: WATCH-2 Study , 2018, Digestive Diseases and Sciences.

[2]  C. Hassan,et al.  Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated October 2017 , 2018, Endoscopy.

[3]  D. Forcione,et al.  Covered versus uncovered self-expandable metal stents for malignant biliary strictures: A meta-analysis and systematic review , 2016, Indian Journal of Gastroenterology.

[4]  Xiujun Cai,et al.  Covered Stents versus Uncovered Stents for Unresectable Malignant Biliary Strictures: A Meta-Analysis , 2016, BioMed research international.

[5]  W. Bernardo,et al.  Endoscopic stenting for inoperable malignant biliary obstruction: A systematic review and meta-analysis. , 2015, World journal of gastroenterology.

[6]  Mengtao Zhou,et al.  Predictors for Occlusion of the First Inserted Metallic Stent in Patients with Malignant Biliary Obstruction , 2015, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[7]  T. Conroy,et al.  Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Vargo,et al.  Self-expandable metal stents versus plastic stents for malignant biliary obstruction: a meta-analysis. , 2015, Gastrointestinal endoscopy.

[9]  E. Steyerberg,et al.  Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial. , 2015, Gastroenterology.

[10]  Yuk Ting Ma,et al.  Cancer Management and Research Dovepress Biliary Stenting in Advanced Malignancy: an Analysis of Predictive Factors for Survival , 2022 .

[11]  Laurentiu M. Pop,et al.  Pancreatic Ductal Adenocarcinoma , 2012, Journal of Investigative Medicine.

[12]  M. Murad,et al.  Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. , 2011, Gastrointestinal endoscopy.

[13]  E. Steyerberg,et al.  Multicenter study evaluating factors for stent patency in patients with malignant biliary strictures: development of a simple score model , 2011, Journal of Gastroenterology.

[14]  S. Biggins,et al.  Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. , 2011, JOP : Journal of the pancreas.

[15]  E. Jonas,et al.  Covered versus uncovered self- expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study , 2010, Journal of Digestive Endoscopy.

[16]  B. Petersen,et al.  A lexicon for endoscopic adverse events: report of an ASGE workshop. , 2010, Gastrointestinal endoscopy.

[17]  Y. Shiratori,et al.  A prospective randomised study of “covered” versus “uncovered” diamond stents for the management of distal malignant biliary obstruction , 2004, Gut.

[18]  Y. Shiratori,et al.  Polyurethane-covered metal stent for management of distal malignant biliary obstruction. , 2002, Gastrointestinal endoscopy.

[19]  Dong Ki Lee,et al.  Features of malignant biliary obstruction affecting the patency of metallic stents: a multicenter study. , 2002, Gastrointestinal endoscopy.

[20]  P. Jowell,et al.  Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. , 1998, Gastrointestinal endoscopy.

[21]  Elliot K Fishman,et al.  Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. , 2014, Radiology.

[22]  A. Barkun,et al.  No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  T. Brunner,et al.  Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.